Dementia with Lewy bodies: Diagnosis and clinical approach

David S. Geldmacher, MD
Department of Neurology, University of Virginia Health System, Charlottesville

Address: David S. Geldmacher, MD, Department of Neurology, University of Virginia Health System, PO Box 800394, Charlottesville, VA 22908; e-mail [email protected]

The author has indicated that he has received grant or research support from the Eisai and Pfizer corporations, is a consultant for the Eisai, Pfizer, and Forest corporations, and is on the speakers’ bureaus of the Eisai, Pfizer, Forest, and Astra-Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

David S. Geldmacher, MD
Department of Neurology, University of Virginia Health System, Charlottesville

Address: David S. Geldmacher, MD, Department of Neurology, University of Virginia Health System, PO Box 800394, Charlottesville, VA 22908; e-mail [email protected]

The author has indicated that he has received grant or research support from the Eisai and Pfizer corporations, is a consultant for the Eisai, Pfizer, and Forest corporations, and is on the speakers’ bureaus of the Eisai, Pfizer, Forest, and Astra-Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

David S. Geldmacher, MD
Department of Neurology, University of Virginia Health System, Charlottesville

Address: David S. Geldmacher, MD, Department of Neurology, University of Virginia Health System, PO Box 800394, Charlottesville, VA 22908; e-mail [email protected]

The author has indicated that he has received grant or research support from the Eisai and Pfizer corporations, is a consultant for the Eisai, Pfizer, and Forest corporations, and is on the speakers’ bureaus of the Eisai, Pfizer, Forest, and Astra-Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.